Daewoong Pharma (069620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.057x

Based on the latest financial reports, Daewoong Pharma (069620) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩57.53 Billion ≈ $38.99 Million USD) by net assets (₩1.00 Trillion ≈ $680.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Daewoong Pharma's balance sheet to measure how much of total assets are equity-financed.

Daewoong Pharma - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Daewoong Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 069620 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Daewoong Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Daewoong Pharma ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Delong Composite Energy Group Co Ltd SHE:000593	0.009x
Bowhead Specialty Holdings Inc. NYSE:BOW	0.143x
Shanghai Fengyuzhu Exhibition Co Ltd Class A SHG:603466	0.017x
Wuhan Keqian Biology Co Ltd SHG:688526	0.042x
Jiangsu Gian Technology Co Ltd SHE:300709	0.215x
Corticeira Amorim LS:COR	0.036x
Scandinavian Tobacco Group A/S CO:STG	0.027x
Zhe Jiang Headman Machinery Co Ltd SHG:688577	0.074x

Annual Cash Flow Conversion Efficiency for Daewoong Pharma (2007–2024)

The table below shows the annual cash flow conversion efficiency of Daewoong Pharma from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 069620 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩926.98 Billion ≈ $628.20 Million	₩51.49 Billion ≈ $34.90 Million	0.056x	-66.35%
2023-12-31	₩802.97 Billion ≈ $544.16 Million	₩132.57 Billion ≈ $89.84 Million	0.165x	+3.52%
2022-12-31	₩741.22 Billion ≈ $502.32 Million	₩118.21 Billion ≈ $80.11 Million	0.159x	+180.10%
2021-12-31	₩702.41 Billion ≈ $476.01 Million	₩39.99 Billion ≈ $27.10 Million	0.057x	-60.80%
2020-12-31	₩695.25 Billion ≈ $471.16 Million	₩100.98 Billion ≈ $68.43 Million	0.145x	+60.35%
2019-12-31	₩635.92 Billion ≈ $430.95 Million	₩57.60 Billion ≈ $39.03 Million	0.091x	+15.90%
2018-12-31	₩607.81 Billion ≈ $411.90 Million	₩47.50 Billion ≈ $32.19 Million	0.078x	-52.52%
2017-12-31	₩631.54 Billion ≈ $427.98 Million	₩103.94 Billion ≈ $70.44 Million	0.165x	+547.03%
2016-12-31	₩604.55 Billion ≈ $409.70 Million	₩15.38 Billion ≈ $10.42 Million	0.025x	-58.87%
2015-12-31	₩580.24 Billion ≈ $393.22 Million	₩35.89 Billion ≈ $24.32 Million	0.062x	+8.59%
2014-12-31	₩455.51 Billion ≈ $308.69 Million	₩25.95 Billion ≈ $17.58 Million	0.057x	-53.94%
2013-12-31	₩437.96 Billion ≈ $296.80 Million	₩54.16 Billion ≈ $36.70 Million	0.124x	+6.17%
2012-12-31	₩386.59 Billion ≈ $261.98 Million	₩45.02 Billion ≈ $30.51 Million	0.116x	-46.45%
2011-12-31	₩362.42 Billion ≈ $245.60 Million	₩78.82 Billion ≈ $53.42 Million	0.217x	+93.60%
2008-12-31	₩278.85 Billion ≈ $188.97 Million	₩31.33 Billion ≈ $21.23 Million	0.112x	+17.33%
2007-12-31	₩269.57 Billion ≈ $182.68 Million	₩25.81 Billion ≈ $17.49 Million	0.096x	--

About Daewoong Pharma

KO:069620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$887.37 Million

₩1.31 Trillion KRW

Market Cap Rank

#9256 Global

#233 in Korea

Share Price

₩113800.00

Change (1 day)

-9.25%

52-Week Range

₩107300.00 - ₩194000.00

All Time High

₩272265.92